In addition, in their cohort, higher sCD200 levels correlated with tumor burden, advanced stages of the disease (Rai III and IV), more courses of treatment received (using the requirement for multiple treatment as a surrogate for worst prognosis) and higher serum β2-microglobulin levels. This evidence concerns the gene HLA-G and neoplasm.